TIGIT and neoplasm: Indeed, targeting NK cell checkpoint receptors using anti-TIGIT and anti-NKG2A mAbs could restore the anti-tumor efficacy of both NK and T cells, and more significantly, that anti-tumor capacity could be amplified using a combination with anti-PD-1/PD-L1 mAbs in various tumor models (6, 15).